Adaptive Biotechnologies Currently Down Nine Consecutive Days, on Pace for Longest Losing Streak Since August 2023 -- Data Talk

Dow Jones11-19

Adaptive Biotechnologies Corp. (ADPT) is currently at $13.54, down $0.17 or 1.24%

 

--Would be lowest close since Sept. 29, 2025, when it closed at $13.46

--On pace for largest percent decrease since Nov. 17, 2025, when it fell 2.77%

--Currently down 11 of the past 12 days

--Currently down nine consecutive days; down 23.02% over this period

--Longest losing streak since Aug. 14, 2023, when it fell for 10 straight trading days

--Worst nine day stretch since the nine days ending Nov. 22, 2024, when it fell 27.73%

--Down 22% month-to-date

--Up 125.85% year-to-date; on pace for best year on record (Based on available data back to June 27, 2019)

--Down 80.01% from its all-time closing high of $67.74 on Jan. 22, 2021

--Up 202.23% from 52 weeks ago (Nov. 19, 2024), when it closed at $4.48

--Down 24.06% from its 52-week closing high of $17.83 on Oct. 20, 2025

--Up 209.84% from its 52-week closing low of $4.37 on Nov. 21, 2024

--Traded as low as $13.28; lowest intraday level since Sept. 29, 2025, when it hit $13.07

--Down 3.14% at today's intraday low

 

All data as of 12:07:50 PM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

November 18, 2025 12:11 ET (17:11 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment